Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 3 Low-grade inflammation in FGID

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 1 Patients cured of HCV infection

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 5 Lipid droplet consumption

Figure 4 Simple perianal fistula

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Figure 3 The T-cell cytokine tree in IBD

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Towards precision PRRT for neuroendocrine tumours

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Complex perianal fistula

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Distribution of markers of active HBV infection

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

Figure 6 Injection of mesenchymal stem cells in perianal fistulas Figure 6 | Injection of mesenchymal stem cells in perianal fistulas. First the fistula internal opening is closed using polygalactin absorbable stitches. Subsequently, a suspension of 120 million mesenchymal stem cells are injected, distributing the cells into the tissue adjacent to all fistula tracts (60 million, blue spots) and internal openings (60 million, yellow spots). Panés, J. & Rimola, J. (2017) Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.104